JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain

Stock Information for JanOne Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About JanOne Inc.

JanOne to Present at the Dawson James 8th Annual Investment Conference
Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference
JanOne to Present In Person and by Video at H.C. Wainwright's 25th Annual Global Investment Conference
JanOne Wins "Best Abstract" Award at the Ohio Society of Interventional Pain Physicians Annual Meeting
JanOne Technologies Announces Closing of Registered Direct Offering Priced At-The-Market under Nasdaq Rules
JanOne Technologies Announces Registered Direct Offering Priced At-The-Market under Nasdaq Rules
JanOne to Present Prior Phase II Data on Diabetic Neuropathy at the Ohio Society of Interventional Pain Physicians Annual Meeting
JanOne files international patent application for methods of using low dose naltrexone to treat chronic pain

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.